Masaki Shimizu1, Mao Mizuta1, Takahiro Yasumi2, Naomi Iwata3, Yuka Okura4, Noriko Kinjo5, Hiroaki Umebayashi6, Tomohiro Kubota7, Yasuo Nakagishi8, Kenichi Nishimura9, Masato Yashiro10, Junko Yasumura11, Kazuko Yamazaki12, Hiroyuki Wakiguchi13, Nami Okamoto14, Masaaki Mori15. 1. Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan. 2. Kyoto University Graduate School of Medicine, Kyoto, Japan. 3. Aichi Children's Health and Medical Center, Obu, Japan. 4. KKR Sapporo Medical Center, Sapporo, Japan. 5. University of the Ryukyus, Nakagami-gun, Japan. 6. Miyagi Children's Hospital, Sendai, Japan. 7. Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan. 8. Hyogo Prefectural Kobe Children's Hospital, Kobe, Japan. 9. Yokohama City University Graduate School of Medicine, Yokohama, Japan. 10. Okayama University Hospital, Okayama, Japan. 11. Hiroshima University Graduate School of Biomedical and Health Sciences, Hiroshima, Japan. 12. Saitama Medical Center, Saitama Medical University, Kawagoe, Japan. 13. Yamaguchi University Graduate School of Medicine, Ube, Japan. 14. Osaka Medical College, Takatsuki, Japan. 15. Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Abstract
OBJECTIVE: To validate whether the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA) is practical in the real world. METHODS: A combination of expert consensus and analysis of real patient data was conducted by a panel of 15 pediatric rheumatologists. A total of 65 profiles comprised 18 patients with systemic JIA-associated MAS and 47 patients with active systemic JIA without evidence of MAS. From these profiles, 10 patient data points for full-blown MAS, 11 patient data points for MAS onset, and 47 patient data points for acute systemic JIA without MAS were evaluated. RESULTS: Evaluation of the classification criteria to discriminate full-blown MAS from acute systemic JIA without MAS showed a sensitivity of 1.000 and specificity of 1.000 at the time of full-blown MAS. Sensitivity was 0.636 and specificity was 1.000 at the time of MAS onset. The number of measurement items that fulfilled the criteria increased in full-blown MAS compared to that at MAS onset. At MAS onset, the positive rates of patients who met the criteria for platelet counts and triglycerides were low, whereas those for aspartate aminotransferase were relatively high. At full-blown MAS, the number of patients who met the criteria for each measurement item increased. CONCLUSION: The classification criteria for MAS complicating systemic JIA had a very high diagnostic performance. However, the diagnostic sensitivity for MAS onset was relatively low. For the early diagnosis of MAS in systemic JIA, the dynamics of laboratory values during the course of MAS should be further investigated.
OBJECTIVE: To validate whether the 2016 American College of Rheumatology/European League Against Rheumatism classification criteria of macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA) is practical in the real world. METHODS: A combination of expert consensus and analysis of real patient data was conducted by a panel of 15 pediatric rheumatologists. A total of 65 profiles comprised 18 patients with systemic JIA-associated MAS and 47 patients with active systemic JIA without evidence of MAS. From these profiles, 10 patient data points for full-blown MAS, 11 patient data points for MAS onset, and 47 patient data points for acute systemic JIA without MAS were evaluated. RESULTS: Evaluation of the classification criteria to discriminate full-blown MAS from acute systemic JIA without MAS showed a sensitivity of 1.000 and specificity of 1.000 at the time of full-blown MAS. Sensitivity was 0.636 and specificity was 1.000 at the time of MAS onset. The number of measurement items that fulfilled the criteria increased in full-blown MAS compared to that at MAS onset. At MAS onset, the positive rates of patients who met the criteria for platelet counts and triglycerides were low, whereas those for aspartate aminotransferase were relatively high. At full-blown MAS, the number of patients who met the criteria for each measurement item increased. CONCLUSION: The classification criteria for MAS complicating systemic JIA had a very high diagnostic performance. However, the diagnostic sensitivity for MAS onset was relatively low. For the early diagnosis of MAS in systemic JIA, the dynamics of laboratory values during the course of MAS should be further investigated.
Authors: Esraa M A Eloseily; Francesca Minoia; Courtney B Crayne; Timothy Beukelman; Angelo Ravelli; Randy Q Cron Journal: ACR Open Rheumatol Date: 2019-07-13
Authors: Bas M Smits; Joris van Montfrans; Samuel A Merrill; Lisette van de Corput; Mariëlle van Gijn; Andrica de Vries; Cor van den Bos; Floor Abbink; Renate G van der Molen; Natasja Dors; Caroline Lindemans; Jaap J Boelens; Stefan Nierkens Journal: J Clin Immunol Date: 2021-03-29 Impact factor: 8.317